ECA39 is a Novel Distant Metastasis-related Biomarker in Colorectal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Sep 29

PMID 17007058

Citations 33

Authors

Reigetsu Yoshikawa

Hidenori Yanagi

Chun-Shen Shen

Yoshinori Fujiwara

Masafumi Noda

Toshihiko Yagyu

Makoto Gega

Tsutomu Oshima

Takehira Yamamura

Haruki Okamura

Yoshiro Nakano

Tomonori Morinaga

Tomoko Hashimoto-Tamaoki

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC).

Methods: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients.

Results: ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P<0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P<0.05).

Conclusion: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine.

Citing Articles

Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer.

Pilkington K, Wieland L, Teng L, Jin X, Storey D, Liu J Cochrane Database Syst Rev. 2022; 11():CD012053.

PMID: 36445793 PMC: 9707730. DOI: 10.1002/14651858.CD012053.pub2.

An overview of branched-chain amino acid aminotransferases: functional differences between mitochondrial and cytosolic isozymes in yeast and human.

Toyokawa Y, Koonthongkaew J, Takagi H Appl Microbiol Biotechnol. 2021; 105(21-22):8059-8072.

PMID: 34622336 DOI: 10.1007/s00253-021-11612-4.

Oncogenes in high grade serous adenocarcinoma of the ovary.

Manasa P, Sidhanth C, Krishnapriya S, Vasudevan S, Ganesan T Genes Cancer. 2021; 11(3-4):122-136.

PMID: 33488950 PMC: 7805537. DOI: 10.18632/genesandcancer.206.

Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.

Young G, Symonds E, Nielsen H, Ferm L, Christensen I, Dekker E Clin Epigenetics. 2021; 13(1):14.

PMID: 33478584 PMC: 7818774. DOI: 10.1186/s13148-020-00999-y.

Differential expression of the BCAT isoforms between breast cancer subtypes.

Shafei M, Flemban A, Daly C, Kendrick P, White P, Dean S Breast Cancer. 2020; 28(3):592-607.

PMID: 33367952 PMC: 8065012. DOI: 10.1007/s12282-020-01197-7.

References

Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T . Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer. 2000; 89(6):1228-35. DOI: 10.1002/1097-0142(20000915)89:6<1228::aid-cncr6>3.0.co;2-o. View

Yoshikawa R, Yanagi H, Hashimoto-Tamaoki T, Morinaga T, Nakano Y, Noda M . Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells. Oncol Rep. 2004; 12(6):1287-93. View

Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama J, Yamamura T . Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001; 61(3):1029-37. View

Noguchi K, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Tani M . Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. Anticancer Res. 1995; 15(2):255-8. View

Ehrke M, Reino J, Eppolito C, Mihich E . The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol. 1983; 5(1):35-42. DOI: 10.1016/0192-0561(83)90069-3. View

Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N . ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A. 1996; 93(14):7143-8. PMC: 38950. DOI: 10.1073/pnas.93.14.7143. View

Weir H, Thun M, Hankey B, Ries L, Howe H, Wingo P . Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003; 95(17):1276-99. DOI: 10.1093/jnci/djg040. View

Reisman D, Elkind N, Roy B, Beamon J, Rotter V . c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ. 1993; 4(2):57-65. View

Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M . Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005; 23(12):2645-54. DOI: 10.1200/JCO.2005.04.126. View

10.

Niwa O, Kumazaki T, Tsukiyama T, Soma G, Miyajima N, YOKORO K . A cDNA clone overexpressed and amplified in a mouse teratocarcinoma line. Nucleic Acids Res. 1990; 18(22):6709. PMC: 332653. DOI: 10.1093/nar/18.22.6709. View

11.

Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S . Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997; 21(1):71-7. View

12.

ODwyer P, Stevenson J . Chemotherapy of advanced colorectal cancer. Cancer Treat Res. 1999; 98:111-52. DOI: 10.1007/978-1-4615-4977-2_5. View

13.

Prochownik E . c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther. 2004; 4(2):289-302. DOI: 10.1586/14737140.4.2.289. View

14.

Hosokawa M, Mizukoshi T, Morikawa K, Xu Z, Kobayashi H . The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother. 1986; 22(3):181-5. PMC: 11038850. DOI: 10.1007/BF00200030. View

15.

Hirose K, Zachariae C, Oppenheim J, Matsushima K . Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res. 1990; 9(4):475-83. View

16.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J . Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-6. DOI: 10.1016/s0140-6736(94)90233-x. View

17.

Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y . Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994; 106(1):42-8. DOI: 10.1016/s0016-5085(94)94217-x. View

18.

Eden A, Simchen G, Benvenisty N . Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 1996; 271(34):20242-5. DOI: 10.1074/jbc.271.34.20242. View

19.

Wagner A, Meyers C, Laimins L, Hay N . c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ. 1993; 4(11):879-83. View

20.

Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M . Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol. 1995; 18(3):216-22. View